Human Genome Sciences Announces Unsolicited Offer from GlaxoSmithKline; HGS Board of Directors Authorizes Exploration of Strategic Alternatives Board believes $13 unsolicited offer does not reflect value inherent in Company Goldman Sachs and Credit Suisse retained to assist with exploration of strategic alternatives Additional information requested from GSK